Works matching IS 00071048 AND DT 2022 AND VI 198 AND IP 2
Results: 31
Corrigendum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Multiple myeloma treatment – should be continued or not?
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 223, doi. 10.1111/bjh.18212
- Publication type:
- Article
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 288, doi. 10.1111/bjh.18200
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- 2022
- Publication type:
- Correction Notice
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. e32, doi. 10.1111/bjh.18228
- By:
- Publication type:
- Article
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. e28, doi. 10.1111/bjh.18224
- By:
- Publication type:
- Article
Is 'ABO‐D' really a ready‐made package? Why these parameters should be analysed separately in correlation studies?
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. e26, doi. 10.1111/bjh.18222
- By:
- Publication type:
- Article
Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 257, doi. 10.1111/bjh.18245
- By:
- Publication type:
- Article
Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 401, doi. 10.1111/bjh.18231
- By:
- Publication type:
- Article
Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 397, doi. 10.1111/bjh.18221
- By:
- Publication type:
- Article
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 328, doi. 10.1111/bjh.18216
- By:
- Publication type:
- Article
Anti‐CD20 therapeutic options in immune‐mediated thrombotic thrombocytopenic purpura.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 225, doi. 10.1111/bjh.18215
- Publication type:
- Article
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 307, doi. 10.1111/bjh.18214
- By:
- Publication type:
- Article
B‐cell lymphoma mimicking relapsing polychondritis.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 222, doi. 10.1111/bjh.18220
- By:
- Publication type:
- Article
End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 333, doi. 10.1111/bjh.18217
- By:
- Publication type:
- Article
Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL‐6 production in lymphoma cells.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 360, doi. 10.1111/bjh.18208
- By:
- Publication type:
- Article
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. e23, doi. 10.1111/bjh.18205
- By:
- Publication type:
- Article
Acute haemolysis following COVID‐19 vaccination in a thalassaemic patient with G6PD deficiency.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 221, doi. 10.1111/bjh.18204
- Publication type:
- Article
Single‐dose (4.5 mg/m<sup>2</sup>) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 373, doi. 10.1111/bjh.18203
- By:
- Publication type:
- Article
Immunochemotherapy versus rituximab in anti‐myelin‐associated glycoprotein neuropathy: A report of 64 patients.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 298, doi. 10.1111/bjh.18202
- By:
- Publication type:
- Article
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 317, doi. 10.1111/bjh.18207
- By:
- Publication type:
- Article
Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 267, doi. 10.1111/bjh.18197
- By:
- Publication type:
- Article
Cyclic‐AMP signalling, MYC and hypoxia‐inducible factor 1α intersect to regulate angiogenesis in B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 349, doi. 10.1111/bjh.18196
- By:
- Publication type:
- Article
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 391, doi. 10.1111/bjh.18192
- By:
- Publication type:
- Article
Haematopoietic stem cell gene therapy in inborn errors of metabolism.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 227, doi. 10.1111/bjh.18179
- By:
- Publication type:
- Article
Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all‐trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 338, doi. 10.1111/bjh.18187
- By:
- Publication type:
- Article
T‐cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single‐centre retrospective analysis of 17 cases.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. e18, doi. 10.1111/bjh.18184
- By:
- Publication type:
- Article
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem‐cell transplantation is a prognostic marker of longer progression‐free survival and overall survival.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 278, doi. 10.1111/bjh.18182
- By:
- Publication type:
- Article
The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 382, doi. 10.1111/bjh.18188
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 217, doi. 10.1111/bjh.17596
- Publication type:
- Article
How I treat triple‐class refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 2, p. 244, doi. 10.1111/bjh.18185
- By:
- Publication type:
- Article